Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

24

Other

3

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Glucocorticoid receptor

21

Mineralocorticoid receptor

21

Arachidonate 5-lipoxygenase

3

Cyclooxygenase-1

3

Cyclooxygenase-2

3

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

24

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1958

21

1987

3

Unknown

3

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Acne rosacea

21

Allergic conjunctivitis

21

Bacterial conjunctivitis

21

Corneal injury

21

Cyclitis

21

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

24

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Active

21

CNS Non-penetrant

3

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Merck Sharp & Dohme

21

Apothekernes Laboratorium For Specialpraeparat

3

Meda Pharmaceuticals

3

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

26

Mixture

1

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

FDA UNII

27

PUBCHEM

26

CAS

25

EPA CompTox

24

ECHA (EC/EINECS)

15

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

ALIMENTARY TRACT AND METABOLISM

2

CARDIOVASCULAR SYSTEM

1

DERMATOLOGICALS

1

RESPIRATORY SYSTEM

1

SENSORY ORGANS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTI-ACNE PREPARATIONS

1

ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS

1

CORTICOSTEROIDS FOR SYSTEMIC USE

1

CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS

1

NASAL PREPARATIONS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE

1

ANTI-ACNE PREPARATIONS FOR TOPICAL USE

1

ANTIINFLAMMATORY AGENTS

1

ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION

1

CORTICOSTEROIDS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Aminosalicylic acid and similar agents

1

Corticosteroids

1

Corticosteroids and antiinfectives in combination

1

Corticosteroids for local oral treatment

1

Corticosteroids, combinations for treatment of acne

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

24

Principal Form

3

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 10 of 27 results

First page disabled
Previous page disabled
1
Next page
Next page

MESALAMINE

4Q81I59GXC

Export Data
Search for Structure

Status:

US Approved Rx (2019)

First approved in 1987

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Arachidonate 5-lipoxygenase

Cyclooxygenase-2

Nitric oxide synthase, inducible

Peroxisome proliferator-activated receptor gamma

apoptotic process

macrophage chemotaxis

reactive oxygen species biosynthetic process

Cyclooxygenase-1

Intermediate conductance calcium-activated potassium channel protein 4

Conditions:

Ulcerative colitis

Mesalamine, also known as Mesalazine or 5-aminosalicylic acid (5-ASA), is an anti-inflammatory drug used to treat inflammation of the digestive tract (Crohn's disease) and mild to moderate ulcerative colitis. Mesalazine is a bowel-specific aminosalic...

ylate drug that is metabolized in the gut and has its predominant actions there, thereby having fewer systemic side effects. As a derivative of salicylic acid, 5-ASA is also an antioxidant that traps free radicals, which are potentially damaging by-products of metabolism. Although the mechanism of action of mesalazine is not fully understood, it appears to be topical rather than systemic. Mucosal production of arachidonic acid metabolites, both through the cyclooxygenase pathways, i.e., prostanoids, and through the lipoxygenase pathways, i.e., leukotrienes and hydroxyeicosatetraenoic acids, is increased in patients with chronic inflammatory bowel disease, and it is possible that mesalazine diminishes inflammation by blocking cyclooxygenase and inhibiting prostaglandin production in the colon. Mesalazine is used for the treatment of active ulcerative proctitis.

DEXAMETHASONE

7S5I7G3JQL

Export Data
Search for Structure

Status:

US Approved Rx (2020)

First approved in 1958

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Glucocorticoid receptor

Glucocorticoid receptor

Mineralocorticoid receptor

Conditions:

Herpes zoster keratitis

Allergic conjunctivitis

Superficial punctate keratitis

Bacterial conjunctivitis

Multiple myeloma

Dexamethasone acetate (NEOFORDEX®) is the acetate salt form of dexamethasone, which is a synthetic glucocorticoid; it combines high anti-inflammatory effects with low mineralocorticoid activity. At high doses (e.g. 40 mg), it reduces the immune respo...

nse. Dexamethasone acetate (NEOFORDEX®) is indicated in adults for the treatment of symptomatic multiple myeloma in combination with other medicinal products. Dexamethasone has been shown to induce multiple myeloma cell death (apoptosis) via a down-regulation of nuclear factor-κB activity and an activation of caspase-9 through second mitochondria-derived activator of caspase (Smac; an apoptosis promoting factor) release. Prolonged exposure was required to achieve maximum levels of apoptotic markers along with increased caspase-3 activation and DNA fragmentation. Dexamethasone also down-regulated anti apoptotic genes and increased IκB-alpha protein levels. Dexamethasone apoptotic activity is enhanced by the combination with thalidomide or its analogues and with proteasome inhibitor (e.g. bortezomib).

ROPIVACAINE, (R)-

0494L275Q6

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Voltage-gated potassium channel subunit Kv1.1

Voltage-gated potassium channel subunit Kv1.5

Conditions:

(R)-Ropivacaine (Dextroropivacaine) is a voltage-dependent potassium channel blocker with local anesthetic activity. (S)-Ropivacaine is a medication used for the production of local or regional anesthesia for surgery and for acute pain management. Ro...

pivacaine shows a difference in channel blockade between two enantiomers, and R-Ropivacaine shows greater cardiotoxicity than (S)-Ropivacaine. (R)-Ropivacaine is the impurity in commercial formulations of Ropivacaine.

Sodium 5-aminosalicylate

8P7PMQ6BTF

Export Data
Search for Structure

Status:

US Approved Rx (2019)

First approved in 1987

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Arachidonate 5-lipoxygenase

Cyclooxygenase-2

Nitric oxide synthase, inducible

Peroxisome proliferator-activated receptor gamma

apoptotic process

macrophage chemotaxis

reactive oxygen species biosynthetic process

Cyclooxygenase-1

Intermediate conductance calcium-activated potassium channel protein 4

Conditions:

Ulcerative colitis

Mesalamine, also known as Mesalazine or 5-aminosalicylic acid (5-ASA), is an anti-inflammatory drug used to treat inflammation of the digestive tract (Crohn's disease) and mild to moderate ulcerative colitis. Mesalazine is a bowel-specific aminosalic...

ylate drug that is metabolized in the gut and has its predominant actions there, thereby having fewer systemic side effects. As a derivative of salicylic acid, 5-ASA is also an antioxidant that traps free radicals, which are potentially damaging by-products of metabolism. Although the mechanism of action of mesalazine is not fully understood, it appears to be topical rather than systemic. Mucosal production of arachidonic acid metabolites, both through the cyclooxygenase pathways, i.e., prostanoids, and through the lipoxygenase pathways, i.e., leukotrienes and hydroxyeicosatetraenoic acids, is increased in patients with chronic inflammatory bowel disease, and it is possible that mesalazine diminishes inflammation by blocking cyclooxygenase and inhibiting prostaglandin production in the colon. Mesalazine is used for the treatment of active ulcerative proctitis.

MESALAMINE HYDROCHLORIDE

LQ7CF8AVM8

Export Data
Search for Structure

Status:

US Approved Rx (2019)

First approved in 1987

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Arachidonate 5-lipoxygenase

Cyclooxygenase-2

Nitric oxide synthase, inducible

Peroxisome proliferator-activated receptor gamma

apoptotic process

macrophage chemotaxis

reactive oxygen species biosynthetic process

Cyclooxygenase-1

Intermediate conductance calcium-activated potassium channel protein 4

Conditions:

Ulcerative colitis

Mesalamine, also known as Mesalazine or 5-aminosalicylic acid (5-ASA), is an anti-inflammatory drug used to treat inflammation of the digestive tract (Crohn's disease) and mild to moderate ulcerative colitis. Mesalazine is a bowel-specific aminosalic...

ylate drug that is metabolized in the gut and has its predominant actions there, thereby having fewer systemic side effects. As a derivative of salicylic acid, 5-ASA is also an antioxidant that traps free radicals, which are potentially damaging by-products of metabolism. Although the mechanism of action of mesalazine is not fully understood, it appears to be topical rather than systemic. Mucosal production of arachidonic acid metabolites, both through the cyclooxygenase pathways, i.e., prostanoids, and through the lipoxygenase pathways, i.e., leukotrienes and hydroxyeicosatetraenoic acids, is increased in patients with chronic inflammatory bowel disease, and it is possible that mesalazine diminishes inflammation by blocking cyclooxygenase and inhibiting prostaglandin production in the colon. Mesalazine is used for the treatment of active ulcerative proctitis.

Dexamethasone 21-sulfate

VMN9Z37FQR

Export Data
Search for Structure

Status:

US Approved Rx (2020)

First approved in 1958

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Glucocorticoid receptor

Glucocorticoid receptor

Mineralocorticoid receptor

Conditions:

Herpes zoster keratitis

Allergic conjunctivitis

Superficial punctate keratitis

Bacterial conjunctivitis

Multiple myeloma

Dexamethasone acetate (NEOFORDEX®) is the acetate salt form of dexamethasone, which is a synthetic glucocorticoid; it combines high anti-inflammatory effects with low mineralocorticoid activity. At high doses (e.g. 40 mg), it reduces the immune respo...

nse. Dexamethasone acetate (NEOFORDEX®) is indicated in adults for the treatment of symptomatic multiple myeloma in combination with other medicinal products. Dexamethasone has been shown to induce multiple myeloma cell death (apoptosis) via a down-regulation of nuclear factor-κB activity and an activation of caspase-9 through second mitochondria-derived activator of caspase (Smac; an apoptosis promoting factor) release. Prolonged exposure was required to achieve maximum levels of apoptotic markers along with increased caspase-3 activation and DNA fragmentation. Dexamethasone also down-regulated anti apoptotic genes and increased IκB-alpha protein levels. Dexamethasone apoptotic activity is enhanced by the combination with thalidomide or its analogues and with proteasome inhibitor (e.g. bortezomib).

DEXAMETHASONE SODIUM SUCCINATE

UZA9VMT64W

Export Data
Search for Structure

Status:

US Approved Rx (2020)

First approved in 1958

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Glucocorticoid receptor

Glucocorticoid receptor

Mineralocorticoid receptor

Conditions:

Herpes zoster keratitis

Allergic conjunctivitis

Superficial punctate keratitis

Bacterial conjunctivitis

Multiple myeloma

Dexamethasone acetate (NEOFORDEX®) is the acetate salt form of dexamethasone, which is a synthetic glucocorticoid; it combines high anti-inflammatory effects with low mineralocorticoid activity. At high doses (e.g. 40 mg), it reduces the immune respo...

nse. Dexamethasone acetate (NEOFORDEX®) is indicated in adults for the treatment of symptomatic multiple myeloma in combination with other medicinal products. Dexamethasone has been shown to induce multiple myeloma cell death (apoptosis) via a down-regulation of nuclear factor-κB activity and an activation of caspase-9 through second mitochondria-derived activator of caspase (Smac; an apoptosis promoting factor) release. Prolonged exposure was required to achieve maximum levels of apoptotic markers along with increased caspase-3 activation and DNA fragmentation. Dexamethasone also down-regulated anti apoptotic genes and increased IκB-alpha protein levels. Dexamethasone apoptotic activity is enhanced by the combination with thalidomide or its analogues and with proteasome inhibitor (e.g. bortezomib).

DEXAMETHASONE SUCCINATE

9UY5TBO121

Export Data
Search for Structure

Status:

US Approved Rx (2020)

First approved in 1958

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Glucocorticoid receptor

Glucocorticoid receptor

Mineralocorticoid receptor

Conditions:

Herpes zoster keratitis

Allergic conjunctivitis

Superficial punctate keratitis

Bacterial conjunctivitis

Multiple myeloma

Dexamethasone acetate (NEOFORDEX®) is the acetate salt form of dexamethasone, which is a synthetic glucocorticoid; it combines high anti-inflammatory effects with low mineralocorticoid activity. At high doses (e.g. 40 mg), it reduces the immune respo...

nse. Dexamethasone acetate (NEOFORDEX®) is indicated in adults for the treatment of symptomatic multiple myeloma in combination with other medicinal products. Dexamethasone has been shown to induce multiple myeloma cell death (apoptosis) via a down-regulation of nuclear factor-κB activity and an activation of caspase-9 through second mitochondria-derived activator of caspase (Smac; an apoptosis promoting factor) release. Prolonged exposure was required to achieve maximum levels of apoptotic markers along with increased caspase-3 activation and DNA fragmentation. Dexamethasone also down-regulated anti apoptotic genes and increased IκB-alpha protein levels. Dexamethasone apoptotic activity is enhanced by the combination with thalidomide or its analogues and with proteasome inhibitor (e.g. bortezomib).

DEXAMETHASONE 21-VALERATE

F2EHP3G50P

Export Data
Search for Structure

Status:

US Approved Rx (2020)

First approved in 1958

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Glucocorticoid receptor

Glucocorticoid receptor

Mineralocorticoid receptor

Conditions:

Herpes zoster keratitis

Allergic conjunctivitis

Superficial punctate keratitis

Bacterial conjunctivitis

Multiple myeloma

Dexamethasone acetate (NEOFORDEX®) is the acetate salt form of dexamethasone, which is a synthetic glucocorticoid; it combines high anti-inflammatory effects with low mineralocorticoid activity. At high doses (e.g. 40 mg), it reduces the immune respo...

nse. Dexamethasone acetate (NEOFORDEX®) is indicated in adults for the treatment of symptomatic multiple myeloma in combination with other medicinal products. Dexamethasone has been shown to induce multiple myeloma cell death (apoptosis) via a down-regulation of nuclear factor-κB activity and an activation of caspase-9 through second mitochondria-derived activator of caspase (Smac; an apoptosis promoting factor) release. Prolonged exposure was required to achieve maximum levels of apoptotic markers along with increased caspase-3 activation and DNA fragmentation. Dexamethasone also down-regulated anti apoptotic genes and increased IκB-alpha protein levels. Dexamethasone apoptotic activity is enhanced by the combination with thalidomide or its analogues and with proteasome inhibitor (e.g. bortezomib).

DEXAMETHASONE SODIUM SULFATE

41B47ECP9F

Export Data
Search for Structure

Status:

US Approved Rx (2020)

First approved in 1958

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Glucocorticoid receptor

Glucocorticoid receptor

Mineralocorticoid receptor

Conditions:

Herpes zoster keratitis

Allergic conjunctivitis

Superficial punctate keratitis

Bacterial conjunctivitis

Multiple myeloma

Dexamethasone acetate (NEOFORDEX®) is the acetate salt form of dexamethasone, which is a synthetic glucocorticoid; it combines high anti-inflammatory effects with low mineralocorticoid activity. At high doses (e.g. 40 mg), it reduces the immune respo...

nse. Dexamethasone acetate (NEOFORDEX®) is indicated in adults for the treatment of symptomatic multiple myeloma in combination with other medicinal products. Dexamethasone has been shown to induce multiple myeloma cell death (apoptosis) via a down-regulation of nuclear factor-κB activity and an activation of caspase-9 through second mitochondria-derived activator of caspase (Smac; an apoptosis promoting factor) release. Prolonged exposure was required to achieve maximum levels of apoptotic markers along with increased caspase-3 activation and DNA fragmentation. Dexamethasone also down-regulated anti apoptotic genes and increased IκB-alpha protein levels. Dexamethasone apoptotic activity is enhanced by the combination with thalidomide or its analogues and with proteasome inhibitor (e.g. bortezomib).

Showing 1 - 10 of 27 results

First page disabled
Previous page disabled
1
Next page
Next page

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1